MX1 and colorectal cancer: Finally, we extended the evaluation of the in vivo antitumor efficacy and tolerability of the VIP236 conjugate by comparing it to commonly utilized anticancer compounds using the MX-1 triple-negative breast cancer (TNBC), NCI-H69 small cell lung cancer (SCLC), and SW480 colorectal cancer (CRC) xenograft mouse models.